SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences,
will be presenting at the Morgan Stanley 15th Annual
Global Healthcare Conference in New York
City.
The live presentation takes place on Monday, September 11 at 11:05am ET (8:05am
PT). The presentation will be webcast and may be
accessed on the Company's website at
http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. The Company markets
INGREZZA® (valbenazine) in the United
States for the treatment of adults with tardive
dyskinesia. INGREZZA is a novel, selective vesicular
monoamine transporter 2 (VMAT2) inhibitor, and is the first and
only FDA-approved product indicated for the treatment of adults
with tardive dyskinesia. The Company's three late-stage
clinical programs are: elagolix, a gonadotropin-releasing hormone
antagonist for women's health that is partnered with AbbVie Inc.;
opicapone, a novel, once-daily, peripherally-acting,
highly-selective catechol-o-methyltransferase inhibitor under
investigation as adjunct therapy to levodopa in Parkinson's
patients; and INGREZZA, a novel, once-daily, selective VMAT2
inhibitor under investigation for the treatment of Tourette
syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-300514871.html
SOURCE Neurocrine Biosciences, Inc.